The Joint Committee on Vaccination and Immunisation (JCVI) uses a different process to NICE when making decisions about drugs, but it comes down to cost-effectiveness all the same. The recommendations are somewhat different – in this appraisal they support HPV vaccinations for MSM contingent on an appropriate price. This seems to point to negotiations over a centrally procured price.
The interim position statement is available here. The “JCVI would now like to invite and consult stakeholders to comment on the validity of the assumptions and findings of the modelling and cost-effectiveness study and the interim advice of the Committee.” Although the study report of the cost-effectiveness analysis not available, which makes it tricky.
The consultation closes on the 7th January 2015.
